In a sham-controlled RCT of 221 men with BPH, the ProVee prostatic urethral stent improved IPSS more than sham at 3 months (9.5 vs 5.6 points, P=.001), with 37.8% improvement from baseline at 12 months and no device-related serious adverse events.
RCTn = 221
Kaplan et al. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia